But the current trial isn't designed to find out if B will address the described issue at all. It's "A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19".
"No drugs are recommended for prophylaxis against infection and hospital admission, as none have yet been shown to prevent covid-19 infection in large scale clinical trials."
"Antivirals, which could be given to inpatients who have not yet reached a critical stage of illness, could perhaps have a prophylactic function."
Maybe B would have a prophylactic function but it'll take a different trial to show it.
I can't help but be reminded of the Prurisol experience in which a Phase 2 trial was conducted with 115 participants to study "Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis". In September of 2016 the Company said:
"We are making progress advancing Prurisol through the clinical pathway. We completed a Phase 2a trial of Prurisol in patients with mild-to-moderate chronic plaque psoriasis in May 2016. The trial successfully achieved its primary endpoint, further validating Prurisol's potential as a novel oral treatment for psoriasis."
In spite of that "success" (some disagree with that characterization) the Company chose to follow up that trial with a 199 participant Phase 2 trial testing the Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis at significantly higher dosages.
We know how that went. Well, we kind of know. At least we know that that was pretty much the last we heard of Prurisol. The word "prurisol" does not appear in the latest 10Q.
We'll never know how a broader test of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis might have gone.
And unless a trial is actually undertaken to test the prophylactic value of B-CV we'll never know how that might work either.
FYI the most recent mention I've seen of the prophylactic potential of B-VC was here, in October:
“During the global COVID-19 pandemic, we selectively formed new external industry partnerships, including this opportunity to research a drug candidate like Brilacidin,” said Aarthi Narayanan, PhD, Associate Professor of Systems Biology in Mason’s College of Science. “In testing at GMU’s BSL-3 lab, we showed that Brilacidin potently inhibits SARS-CoV-2 in vitro against the live virus. Beyond exhibiting treatment potential for those already infected by COVID-19, Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic. I look forward to working with Innovation to investigate further Brilacidin’s antiviral properties,” Narayanan added.
I hope she mentions it to Innovation, who didn't mention a prophylactic use at all in its recent 10Q.
I'm tryin ta think but nuttin happens......Curly
